Mark Neumann Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 week, 1 day ago
Mark Neumann has an estimated net worth of at least $22.5 million*, as of Dec. 18, 2024. They own 29,700 shares of ITCI stock. They have sold 339,537 shares of ITCI stock since 2021, for an estimated $19.8 million.
Mark Neumann $ITCI SEC Form 4 Insider Trading
Mark Neumann has filed a total of 41 insider trades in $ITCI since 2021. Their most recent trade was a sale of 18,714 shares, made on Aug 16, 2024. Their largest trade was a sale of 55,300 shares, made on Aug 07, 2023. We estimate that they now own 29,700 shares of $ITCI, worth an estimated $2.6 million.
Insider Trading at $ITCI
There have been a total of 247 insider trades reported at $ITCI since 2021, with 0 shares purchased and 3.0 million shares sold. The most active insider traders in $ITCI stock have been Sharon Mates, Mark Neumann, and Michael Halstead. The most recent trade was a sale of 27,667 shares reported by Sharon Mates (Chairman and CEO), made on Dec 04, 2024.
History of Insider Stock Trades by Mark Neumann
Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
---|---|---|---|---|
ITCI | Sale | 18,714 | Aug 16, 2024 | Aug. 20, 2024, 6:03 p.m. |
ITCI | Sale | 4,496 | Mar 07, 2024 | March 11, 2024, 8:31 p.m. |
ITCI | Sale | 8,636 | Mar 07, 2024 | March 11, 2024, 8:31 p.m. |
ITCI | Sale | 1,313 | Mar 11, 2024 | March 11, 2024, 8:31 p.m. |
ITCI | Sale | 1,729 | Mar 11, 2024 | March 11, 2024, 8:31 p.m. |
ITCI | Sale | 4,303 | Mar 11, 2024 | March 11, 2024, 8:31 p.m. |
ITCI | Sale | 200 | Feb 26, 2024 | Feb. 27, 2024, 8:58 p.m. |
ITCI | Sale | 2,341 | Feb 26, 2024 | Feb. 27, 2024, 8:58 p.m. |
ITCI | Sale | 4,059 | Feb 26, 2024 | Feb. 27, 2024, 8:58 p.m. |
ITCI | Sale | 1,307 | Feb 26, 2024 | Feb. 27, 2024, 8:58 p.m. |
ITCI | Sale | 4,956 | Feb 02, 2024 | Feb. 5, 2024, 7:07 p.m. |
ITCI | Sale | 6,904 | Feb 02, 2024 | Feb. 5, 2024, 7:07 p.m. |
ITCI | Sale | 15,639 | Nov 06, 2023 | Nov. 8, 2023, 6:31 p.m. |
ITCI | Sale | 26,754 | Nov 06, 2023 | Nov. 8, 2023, 6:31 p.m. |
ITCI | Sale | 55,300 | Aug 07, 2023 | Aug. 9, 2023, 6:05 p.m. |
ITCI | Sale | 10,183 | Mar 28, 2023 | March 30, 2023, 5:08 p.m. |
ITCI | Sale | 5,421 | Mar 28, 2023 | March 30, 2023, 5:08 p.m. |
ITCI | Sale | 6,750 | Mar 10, 2023 | March 13, 2023, 7:35 p.m. |
ITCI | Sale | 423 | Mar 13, 2023 | March 13, 2023, 7:35 p.m. |
ITCI | Sale | 3,335 | Mar 13, 2023 | March 13, 2023, 7:35 p.m. |
ITCI | Sale | 1,800 | Mar 10, 2023 | March 13, 2023, 7:35 p.m. |
ITCI | Sale | 7,241 | Mar 01, 2023 | March 3, 2023, 8:03 p.m. |
ITCI | Sale | 4,046 | Feb 24, 2023 | Feb. 27, 2023, 9:03 p.m. |
ITCI | Sale | 635 | Feb 21, 2023 | Feb. 22, 2023, 9:05 p.m. |
ITCI | Sale | 123 | Feb 21, 2023 | Feb. 22, 2023, 9:05 p.m. |
ITCI | Sale | 3,140 | Feb 21, 2023 | Feb. 22, 2023, 9:05 p.m. |
ITCI | Sale | 14,885 | Apr 08, 2022 | April 8, 2022, 6:56 p.m. |
ITCI | Sale | 53,987 | Apr 08, 2022 | April 8, 2022, 6:56 p.m. |
ITCI | Sale | 17,476 | Apr 08, 2022 | April 8, 2022, 6:56 p.m. |
ITCI | Sale | 1,371 | Feb 24, 2022 | Feb. 25, 2022, 8:08 p.m. |
ITCI | Sale | 3,875 | Feb 24, 2022 | Feb. 25, 2022, 8:08 p.m. |
ITCI | Sale | 2,660 | Feb 24, 2022 | Feb. 25, 2022, 8:08 p.m. |
ITCI | Sale | 4,607 | Feb 22, 2022 | Feb. 23, 2022, 8:07 p.m. |
ITCI | Sale | 6,532 | Feb 22, 2022 | Feb. 23, 2022, 8:07 p.m. |
ITCI | Sale | 4,252 | Jan 10, 2022 | Jan. 11, 2022, 9:06 p.m. |
ITCI | Sale | 13,935 | Jan 10, 2022 | Jan. 11, 2022, 9:06 p.m. |
ITCI | Sale | 2,761 | Jan 10, 2022 | Jan. 11, 2022, 9:06 p.m. |
ITCI | Sale | 500 | Oct 18, 2021 | Oct. 18, 2021, 8 p.m. |
ITCI | Sale | 1,958 | Oct 18, 2021 | Oct. 18, 2021, 8 p.m. |
ITCI | Sale | 4,288 | Oct 18, 2021 | Oct. 18, 2021, 8 p.m. |
ITCI | Sale | 6,702 | Oct 18, 2021 | Oct. 18, 2021, 8 p.m. |
$ITCI Executives and Stock Owners with Insider Trades
-
Sharon Mates, Chairman, President & CEO
-
Mark Neumann, EVP, Chief Commercial Officer
-
Michael Halstead, EVP and General Counsel
-
Lawrence J. Hineline, SVP of Finance CFO
-
Sharon Mates, Chairman and CEO
-
Suresh K. Durgam, EVP, Chief Medical Officer
-
Lawrence J. Hineline, SVP of Finance, CFO
-
Suresh K. Durgam, Chief Medical Officer
-
Michael Halstead, President
-
Suresh K. Durgam, SVP, Chief Medical Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.